Virpax Pharmaceuticals (VRPX) Competitors

$0.0005 0.00 (0.00%)

As of 05/4/2026

VRPX vs. CMRA, PXMD, CALA, CLVR, and EFTR

Should you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include Comera Life Sciences (CMRA), PaxMedica (PXMD), Calithera Biosciences (CALA), Clever Leaves (CLVR), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry.

How does Virpax Pharmaceuticals compare to Comera Life Sciences?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

: In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.
Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Comera Life Sciences Neutral
: Virpax Pharmaceuticals has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Comera Life Sciences has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
: 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Virpax Pharmaceuticals has higher earnings, but lower revenue than Comera Life Sciences. Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A
Comera Life Sciences $1.00M 0.00 -$18M -$0.31 N/A
: Comera Life Sciences' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Virpax Pharmaceuticals N/A -1,554.34% -338.29%
Comera Life Sciences N/A N/A N/A

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
Comera Life Sciences	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
Comera Life Sciences	$1.00M	0.00	-$18M	-$0.31	N/A

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
Comera Life Sciences	N/A	N/A	N/A

Summary

Comera Life Sciences beats Virpax Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to PaxMedica?

Virpax Pharmaceuticals (NASDAQ:VRPX) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

: Virpax Pharmaceuticals' return on equity of -1,554.34% beat PaxMedica's return on equity.
Company Net Margins Return on Equity Return on Assets
Virpax Pharmaceuticals N/A -1,554.34% -338.29%
PaxMedica N/A -3,167.89% -560.35%
: Virpax Pharmaceuticals has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500. Comparatively, PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the S&P 500.
: In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.
Company Overall Sentiment
Virpax Pharmaceuticals Neutral
PaxMedica Neutral
: 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.9% of PaxMedica shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 1.0% of PaxMedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: PaxMedica is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A
PaxMedica N/A N/A -$18.29M -$6.09 N/A

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
PaxMedica	N/A	-3,167.89%	-560.35%

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
PaxMedica	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A

Summary

Virpax Pharmaceuticals beats PaxMedica on 7 of the 8 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Calithera Biosciences?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

: Calithera Biosciences' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Virpax Pharmaceuticals N/A -1,554.34% -338.29%
Calithera Biosciences N/A N/A N/A
: Virpax Pharmaceuticals has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of -1.06, indicating that its share price is 206% less volatile than the S&P 500.
: In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.
Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Calithera Biosciences Neutral
: 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A
Calithera Biosciences N/A N/A -$39.65M N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
Calithera Biosciences	N/A	N/A	N/A

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
Calithera Biosciences	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A

Summary

Virpax Pharmaceuticals beats Calithera Biosciences on 4 of the 7 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Clever Leaves?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

: Virpax Pharmaceuticals has higher earnings, but lower revenue than Clever Leaves. Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A
Clever Leaves $17.42M 0.00 -$17.90M -$12.36 N/A
: Virpax Pharmaceuticals has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Clever Leaves has a beta of 4212.86, meaning that its share price is 421,186% more volatile than the S&P 500.
: 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 6.9% of Clever Leaves shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Comparatively, 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Clever Leaves' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Virpax Pharmaceuticals N/A -1,554.34% -338.29%
Clever Leaves N/A N/A N/A
: In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.
Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Clever Leaves Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
Clever Leaves	N/A	N/A	N/A

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
Clever Leaves	Neutral

Summary

Clever Leaves beats Virpax Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to eFFECTOR Therapeutics?

Virpax Pharmaceuticals (NASDAQ:VRPX) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

: eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A
eFFECTOR Therapeutics N/A N/A -$35.81M -$13.08 N/A
: Virpax Pharmaceuticals has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, eFFECTOR Therapeutics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500.
: 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: eFFECTOR Therapeutics' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Virpax Pharmaceuticals N/A -1,554.34% -338.29%
eFFECTOR Therapeutics N/A N/A N/A
: In the previous week, eFFECTOR Therapeutics had 1 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 1 mentions for eFFECTOR Therapeutics and 0 mentions for Virpax Pharmaceuticals. Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.
Company Overall Sentiment
Virpax Pharmaceuticals Neutral
eFFECTOR Therapeutics Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
eFFECTOR Therapeutics	N/A	N/A	-$35.81M	-$13.08	N/A

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
eFFECTOR Therapeutics	N/A	N/A	N/A

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
eFFECTOR Therapeutics	Neutral

Summary

eFFECTOR Therapeutics beats Virpax Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get Virpax Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRPX vs. The Competition

Export

Metric	Virpax Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1K	$892.88M	$6.25B	$11.87B
Dividend Yield	N/A	4.84%	2.73%	5.21%
P/E Ratio	0.00	1.72	29.04	28.47
Price / Sales	N/A	120.50	476.61	60.94
Price / Cash	N/A	20.07	27.62	36.52
Price / Book	0.00	7.60	9.67	6.67
Net Income	-$15.19M	-$4.80M	$3.55B	$332.53M
7 Day Performance	N/A	-0.02%	1.70%	2.01%
1 Month Performance	N/A	5.52%	5.62%	9.20%
1 Year Performance	N/A	30.99%	34.42%	39.59%

Virpax Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRPX Virpax Pharmaceuticals	N/A	$0.00 flat	N/A	N/A	$1K	N/A	N/A	7	Upcoming Earnings
CMRA Comera Life Sciences	N/A	N/A	N/A	N/A	$3K	$1.00M	N/A	2
PXMD PaxMedica	N/A	$0.00 flat	N/A	N/A	$2K	N/A	N/A	2
CALA Calithera Biosciences	N/A	$0.00 flat	N/A	N/A	$1K	N/A	N/A	60	High Trading Volume
CLVR Clever Leaves	N/A	$0.00 flat	N/A	N/A	$1K	$17.42M	N/A	560

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRPX) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virpax Pharmaceuticals (VRPX) Competitors

VRPX vs. CMRA, PXMD, CALA, CLVR, and EFTR

How does Virpax Pharmaceuticals compare to Comera Life Sciences?

Summary

How does Virpax Pharmaceuticals compare to PaxMedica?

Summary

How does Virpax Pharmaceuticals compare to Calithera Biosciences?

Summary

How does Virpax Pharmaceuticals compare to Clever Leaves?

Summary

How does Virpax Pharmaceuticals compare to eFFECTOR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRPX vs. The Competition

Virpax Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virpax Pharmaceuticals (VRPX) Competitors

VRPX vs. CMRA, PXMD, CALA, CLVR, and EFTR

How does Virpax Pharmaceuticals compare to Comera Life Sciences?

Summary

How does Virpax Pharmaceuticals compare to PaxMedica?

Summary

How does Virpax Pharmaceuticals compare to Calithera Biosciences?

Summary

How does Virpax Pharmaceuticals compare to Clever Leaves?

Summary

How does Virpax Pharmaceuticals compare to eFFECTOR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRPX vs. The Competition

Virpax Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools